



Test our new Cav1.2 cell line

Cardiac Ion Channel Panel

In line with the currently discussed shift in cardiac safety assessment from a mere hERG screening to a more comprehensive evaluation of multiple ion channel effects we offer a premium panel of CiPA-compliant human cardiac ion channel assays.

Our cardiac safety panel includes the key cardiac channels, thus providing a robust, cost-effective approach to cardiac liability testing.

Cardiac Ion Channels	Function
hERG	delayed rectifier potassium current ($I_{\rm kr}$)
Cav1.2	L-type calcium current (I _{ca})
Nav1.5	sodium current (I _{Na})
Kir2.1	inward rectifier potassium current (${\rm I}_{{\rm K1}}$)
KvLQT1/minK	delayed rectifier potassium current (${\rm I}_{\rm \scriptscriptstyle KS}$)
Kv4.3	transient outward potassium current (\mathbf{I}_{to})
Kv1.5	delayed rectifier potassium current ($I_{_{Kur}}$)

According to your needs in drug testing, we apply high fidelity gigaseal automated patch clamp platforms and/or conventional manual patch clamp for ion channel screening and concentration-response testing.





Our Cardiac Ion Channel Panel services as well as our related Multiwell Cardiac Screen assay using human cardiomyocytes allow a greater insight into potential cardiac risk, and enable a more effective decision-making in early preclinical development.

NMI TT Pharmaservices Markwiesenstraβe 55 72770 Reutlingen, Germany Phone +49 7121 51530-0 Fax +49 7121 51530-16 www.nmi-tt.de Contact Dr. Timm Danker Phone +49 7121 51530-896 danker@nmi-tt.de

Dr. Udo Kraushaar Phone +49 7121 51530-851 kraushaar@nmi-tt.de www.nmi-tt.de/ephys